Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
1Q17
1Q16
$ Change
% Change
Spine
$11.7
$11.1
$0.6
5.1%
Orthobiologics
$10.4
$9.8
$0.5
5.5%
Total
$22.1
$21.0
$1.1
5.3%
Three priorities for 2017: revise strategic position/goals, optimize the sales channel and improve inventory utilization
Majority of YoY growth derived from increase in revenue from biologics: 3Demin 1Q17 revenue $1.6MM, +71% vs. 1Q16; OsteoVive is fastest-growing revenue category company’s biologic portfolio; OsteoSponge showing double-digit growth vs. 1Q16
Will address portfolio gaps via licensing agreements (in final stages for a few of them, presently)
Revenue from top 10 distributors grew +44% vs. 1Q16, generating 60% of commissioned revenue
Guidance update: withdrew previously-provided 2017 guidance (in a range from $96.0MM to $98.0MM) in light of ongoing review of its capital structure with Orbimed, its principle debt holder; update to come after review is complete
Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
Q17 Q16 $ Change % Change
Spine $11.7 $11.1 $0.6 ...
Xtant Medical posted 1Q17 revenue of US $22.1MM, +5.3% vs. 1Q16.
ORTHOWORLD estimates segment revenue and as-reported growth as follows.
1Q17
1Q16
$ Change
% Change
Spine
$11.7
$11.1
$0.6
5.1%
Orthobiologics
$10.4
$9.8
$0.5
5.5%
Total
$22.1
$21.0
$1.1
5.3%
Three priorities for 2017: revise strategic position/goals, optimize the sales channel and improve inventory utilization
Majority of YoY growth derived from increase in revenue from biologics: 3Demin 1Q17 revenue $1.6MM, +71% vs. 1Q16; OsteoVive is fastest-growing revenue category company’s biologic portfolio; OsteoSponge showing double-digit growth vs. 1Q16
Will address portfolio gaps via licensing agreements (in final stages for a few of them, presently)
Revenue from top 10 distributors grew +44% vs. 1Q16, generating 60% of commissioned revenue
Guidance update: withdrew previously-provided 2017 guidance (in a range from $96.0MM to $98.0MM) in light of ongoing review of its capital structure with Orbimed, its principle debt holder; update to come after review is complete
Copy to clipboard 
